• Tarsus Pharmaceuticals Inc TARS.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of seven analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -99 cents to -54 cents per share.

• Revenue rose 183.7% to $78.34 million from a year ago; analysts expected $72.47 million.

• Tarsus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 64 cents​.

• The company reported a quarterly loss of $25.12 million.

• Tarsus Pharmaceuticals Inc shares had risen by 1.1% this quarter and lost 6.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 20.6% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $73.00

This summary was machine generated from LSEG data May 2 at 04:36 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)